Affinage

CLDN6

Claudin-6 · UniProt P56747

Length
220 aa
Mass
23.3 kDa
Annotated
2026-06-09
46 papers in source corpus 24 papers cited in narrative 25 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

CLDN6 is a tetraspan tight junction membrane protein that functions as a context-dependent signaling hub, coupling its C-terminal cytoplasmic tail to scaffold and kinase partners to control proliferation, differentiation, metabolism, and cell death—most extensively characterized in breast cancer but also acting in gastric, hepatocellular, colorectal, and lung tumors (PMID:39169280, PMID:37443730, PMID:31827075). Correct membrane targeting of CLDN6 depends on its cytoplasmic tail, whose deletion mislocalizes CLDN6 and partner claudins and disrupts epidermal and hair-follicle differentiation in vivo (PMID:16847338, PMID:15908185). Many of its signaling functions are routed through a C-terminal PDZ-binding motif that docks scaffold proteins: CLDN6 binds ZO-1 to assemble a PTEN-containing complex that stabilizes p53 by restraining AKT/MDM2-mediated ubiquitination (PMID:37852424), binds MAGI2 to block KLF5/SREBF1-driven palmitate synthesis and thereby impair oncogenic RAS palmitoylation and membrane localization (PMID:39169280), and binds LKB1 to activate AMPK/ULK1-dependent autophagy (PMID:40959289). CLDN6 also engages SRC-family kinases BLK and SRC directly through its C-terminal domain in a phosphotyrosine-independent manner, and these kinases are required for CLDN6-triggered epithelial differentiation (PMID:37443730). A recurring tumor-suppressive theme is restraint of growth-promoting kinase cascades and reprogramming of metabolism: CLDN6 suppresses ERK signaling via AF-6/afadin and the ERK/Sp1/cyclin D1 and ERK/IL-8 axes (PMID:29159771, PMID:35752352), activates ASK1- and RIP1/JNK-dependent pathways to drive apoptosis and suppress aerobic glycolysis (PMID:27035750, PMID:38462752), and lowers TAZ to dampen c-MYC-driven glycolysis (PMID:35008557). CLDN6 expression is silenced by promoter DNA methylation across esophageal, lung, and other carcinomas, with TGFβ/SMAD2 signaling driving DNMT1 recruitment to the CLDN6 promoter (PMID:19288010, PMID:28867761, PMID:38462752). Its activity is not uniformly suppressive: by interacting with LATS1/2 or a TJP2 complex, CLDN6 can promote YAP1 nuclear entry to drive EMT and lineage shifts, producing oncogenic outcomes in gastric and hepatocellular carcinoma (PMID:31827075, PMID:33536280).

Mechanistic history

Synthesis pass · year-by-year structured walk · 11 steps
  1. 2006 High

    Established that the CLDN6 cytoplasmic tail is required for correct membrane targeting and that CLDN6 dosage and localization control epidermal differentiation, defining its first in vivo physiological role.

    Evidence Tail-truncation and overexpression transgenic mouse models with histology, immunofluorescence, and differentiation-marker western blots

    PMID:15908185 PMID:16847338

    Open questions at the time
    • Does not define the molecular partners bound by the tail in epidermis
    • Mechanism linking mislocalization to the unfolding-protein response not resolved
  2. 2009 Medium

    Showed that loss of CLDN6 in carcinoma is driven by promoter DNA methylation, establishing an epigenetic silencing mechanism for its downregulation.

    Evidence Promoter methylation analysis and 5-aza-2'-deoxycytidine demethylation-restoration in esophageal squamous carcinoma cell lines

    PMID:19288010

    Open questions at the time
    • Did not identify the upstream signal directing methylation
    • Functional consequence of restored CLDN6 not tested here
  3. 2017 Medium

    Connected an upstream signaling input to CLDN6 silencing by showing TGFβ/SMAD2 drives DNMT1 binding and methylation of the CLDN6 promoter, placing CLDN6 loss within EMT programs.

    Evidence ChIP for DNMT1 promoter occupancy, SB431542 inhibition, and CLDN6 siRNA rescue in cancer cells

    PMID:28867761

    Open questions at the time
    • Does not establish which cancer contexts depend on this axis
    • SMAD2-independent silencing routes not excluded
  4. 2017 Medium

    Demonstrated that CLDN6 physically engages signaling and scaffold partners (p53, AF-6) to control chemoresistance and ERK signaling, opening the model of CLDN6 as a membrane-anchored signaling regulator rather than a passive junction protein.

    Evidence Co-IP, co-localization, RNAi/overexpression, and pharmacological rescue (PMA) in breast cancer cells

    PMID:29116019 PMID:29159771

    Open questions at the time
    • Direct versus indirect nature of the p53 interaction not structurally resolved
    • Whether the PDZ motif mediates these interactions not tested in these studies
  5. 2016 Medium

    Placed CLDN6 upstream of an ASK1-p38/JNK apoptotic cascade, linking CLDN6 restoration to stress-kinase-driven cell death.

    Evidence Stable transfection, ASK1 pharmacological inhibition (TRX1), TUNEL, and apoptosis-marker western blots in MCF-7 cells

    PMID:27035750

    Open questions at the time
    • No direct CLDN6-ASK1 binding shown
    • Mechanism reducing ASK1 Ser967 phosphorylation unresolved
  6. 2019 Medium

    Revealed opposing roles for CLDN6 in Hippo signaling—suppressing LATS1/2 to promote oncogenic YAP1/EMT in gastric cancer versus inducing autophagy downstream of ERβ in breast cancer—establishing its context-dependent output.

    Evidence Co-IP and phosphorylation assays for LATS1/2-YAP1; ChIP, luciferase, beclin1-knockdown rescue, and xenografts for ERβ/CLDN6/autophagy

    PMID:31412908 PMID:31827075

    Open questions at the time
    • What determines tumor-suppressive versus oncogenic Hippo output not defined
    • Direct LATS1/2 binding interface not mapped
  7. 2020 Medium

    Extended CLDN6's regulatory reach to hypoxia and Wnt signaling by showing it sequesters β-catenin to drive HIF-1α degradation through a SENP1-dependent feedback loop.

    Evidence RNAi, ChIP, mRNA sequencing, and metastasis assays with clinical samples in breast cancer

    PMID:32093760

    Open questions at the time
    • Direct CLDN6-β-catenin binding interface not defined
    • Generality beyond breast cancer untested
  8. 2021 Medium

    Defined CLDN6 as a metabolic regulator by showing TJP2-dependent YAP1 activation and TAZ-dependent c-MYC suppression of glycolysis, linking junctional partners to tumor energy metabolism and lineage.

    Evidence Co-IP, metabolomic lactate/glucose measurements, and functional assays in hepatocellular and breast cancer cells

    PMID:33536280 PMID:35008557

    Open questions at the time
    • How CLDN6 chooses between TAZ suppression and TJP2/YAP1 activation unresolved
    • TAZ degradation mechanism not defined
  9. 2023 High

    Anchored CLDN6 signaling to its PDZ-binding motif and SRC-family kinases, showing direct, phosphotyrosine-independent binding of BLK and SRC required for differentiation and PDZ-motif-dependent assembly of ZO-1/PTEN and JNK/c-Jun complexes.

    Evidence Recombinant-protein pull-downs and double-knockout F9 cells for BLK/SRC; Co-IP, ChIP, luciferase, and in vivo metastasis models for ZO-1/PTEN and JNK/c-Jun

    PMID:36935496 PMID:37443730 PMID:37852424

    Open questions at the time
    • Structural basis of PDZ-partner selectivity not determined
    • Whether SRC-family binding and PDZ-scaffold binding are mutually exclusive unknown
  10. 2024 Medium

    Expanded the CLDN6 scaffold network to metabolic and stress-kinase control, with MAGI2 binding restraining SREBF1/RAS palmitoylation and RIP1 binding activating ASK1/JNK to suppress glycolysis in lung cancer.

    Evidence Co-IP, IP-ABE acyl-biotin exchange, ChIP, and xenografts (breast); Co-IP, methylation-specific PCR, and Seahorse assays (NSCLC)

    PMID:38462752 PMID:39169280

    Open questions at the time
    • RIP1 interaction shown by Co-IP without direct binding validation
    • Cross-talk between these parallel CLDN6 outputs unmapped
  11. 2025 Medium

    Established CLDN6 as a controller of autophagy and ferroptosis through LKB1/AMPK/ULK1 and DLG1/PBK/NRF2 axes, showing both protective (chemoresistance) and lethal (ferroptosis) outcomes depending on partner engagement.

    Evidence Co-IP, autophagy and ferroptosis assays, UPS-inhibition rescue, and in vivo models in breast cancer

    PMID:39984471 PMID:40959289

    Open questions at the time
    • What dictates protective versus lethal autophagy outcome unresolved
    • PBK recruitment via the endosomal pathway mechanistically incomplete

Open questions

Synthesis pass · forward-looking unresolved questions
  • It remains unresolved what molecular switch determines whether CLDN6 acts as a tumor suppressor or oncogene across tissues, and whether a unifying biochemical rule governs PDZ-partner selection and the divergent downstream outcomes.
  • No structural model of CLDN6 PDZ-motif/partner complexes
  • Context-determining factors for opposing Hippo, autophagy, and metabolic outputs unknown
  • Native tight-junction barrier function relative to signaling role not directly compared

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0060090 molecular adaptor activity 4 GO:0140313 molecular sequestering activity 4 GO:0005198 structural molecule activity 2
Localization
GO:0005886 plasma membrane 3 GO:0005829 cytosol 2 GO:0005768 endosome 1
Pathway
R-HSA-162582 Signal Transduction 4 R-HSA-9612973 Autophagy 4 R-HSA-1266738 Developmental Biology 3 R-HSA-1430728 Metabolism 3 R-HSA-5357801 Programmed Cell Death 3
Partners
AF-6LATS1LKB1MAGI2RIP1SRCTAZTJP2

Evidence

Reading pass · 25 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2019 CLDN6 reduces phosphorylation of LATS1/2 and YAP1 by directly interacting with LATS1/2 in the Hippo signaling pathway, thereby promoting YAP1 nuclear entry; nuclear YAP1 then interacts with Snail1 to drive EMT and enhance gastric cancer cell invasiveness. Co-immunoprecipitation, western blot (phosphorylation assays), in vitro and in vivo functional assays Cell death & disease Medium 31827075
2021 CLDN6 interacts with TJP2 (tight junction protein 2), and this CLDN6/TJP2 complex activates YAP1 via the Hippo signaling pathway, inducing phenotypic shift of hepatocellular carcinoma cells from hepatic to biliary lineage and conferring sorafenib resistance. Co-immunoprecipitation, functional cell line assays, overexpression studies Science translational medicine Medium 33536280
2019 ERβ transcriptionally upregulates CLDN6 expression (confirmed by ChIP and dual luciferase reporter assays), and CLDN6 in turn positively regulates beclin1 to induce beclin1-dependent autophagy, thereby inhibiting breast cancer cell migration and invasion. ChIP assay, dual luciferase reporter assay, western blot, immunofluorescence, transmission electron microscopy, xenograft mouse models Journal of experimental & clinical cancer research High 31412908
2016 CLDN6 restoration in MCF-7 breast cancer cells decreases ASK1 phosphorylation at Ser967, activating downstream JNK and p38 kinase; inhibition of ASK1 with TRX1 suppressed JNK/p38 activation, reversed apoptosis, and increased Bcl-2/Bax ratio and reduced caspase-3 cleavage, placing CLDN6 upstream of the ASK1-p38/JNK apoptotic pathway. Stable transfection, pharmacological inhibition (TRX1), TUNEL staining, DNA ladder, western blot, colony formation assay International journal of oncology Medium 27035750
2017 CLDN6 interacts with p53 and promotes translocation of p53 from nucleus to cytoplasm; this nuclear exclusion of p53 upregulates GSTP1 expression and GST enzyme activity, conferring chemoresistance to adriamycin, 5-FU, and cisplatin in breast cancer cells. Co-immunoprecipitation, RNAi knockdown/overexpression, CCK-8 cytotoxicity assay, GST activity kit, western blot Journal of experimental & clinical cancer research Medium 29116019
2017 CLDN6 co-localizes and physically interacts with AF-6 (afadin); CLDN6 overexpression increases AF-6 expression and suppresses ERK signaling activation, upregulating cancer stem cell markers (OCT4, SOX2, Nanog) and enhancing chemoresistance to adriamycin in TNBC cells. ERK activator PMA reversed these effects. Co-immunoprecipitation, co-localization (immunofluorescence), pharmacological rescue (PMA), western blot, IC50 assay Molecular and cellular biochemistry Medium 29159771
2020 CLDN6 interacts with and sequesters β-catenin in the cytoplasm, promoting its degradation and preventing nuclear translocation; this reduces SENP1 expression, prevents deSUMOylation of HIF-1α, and ultimately leads to HIF-1α degradation, forming a negative feedback loop with HIF-1α under hypoxic conditions in breast cancer. RNAi, ChIP assay, mRNA sequencing, KEGG pathway analysis, functional metastasis assays, clinical sample analysis Journal of experimental & clinical cancer research Medium 32093760
2006 The cytoplasmic tail domain of CLDN6 is required for correct membrane targeting; deletion of the tail (CDelta187) causes mislocalization of CLDN6 and other claudins (CLDN10, CLDN11, CLDN18) to the cytoplasm, activates a protein-unfolding pathway, and triggers postnatal epidermal hyperproliferation and aberrant differentiation in transgenic mice. Structure-function transgenic mouse model (tail-truncation mutant), immunofluorescence, histological analysis, western blot Molecular and cellular biology High 16847338
2005 Overexpression of CLDN6 in transgenic mouse epidermis perturbs epidermal differentiation, induces expression of CLDN5 and CLDN8 (not normally detectable), alters hair follicle differentiation (shorter anagen phase, altered hair type distribution), and disrupts expression of late differentiation markers (profilaggrin/filaggrin, loricrin, transglutaminase 3), establishing CLDN6 as a regulator of epidermal and follicular differentiation. Transgenic mouse overexpression (involucrin promoter), histological analysis, immunohistochemistry, western blot Mechanisms of development Medium 15908185
2017 SMAD2 signaling upregulates DNMT1, which methylates the CLDN6 promoter to silence CLDN6 expression; blocking SMAD2 with SB431542 decreases DNMT1 binding to the CLDN6 promoter, reduces promoter methylation, increases CLDN6 protein, and suppresses EMT, migration and invasion; knockdown of CLDN6 abolishes these SB431542 effects. ChIP assay (DNMT1 binding to CLDN6 promoter), pharmacological inhibition (SB431542), CLDN6 siRNA knockdown, western blot, migration/invasion assays International journal of molecular sciences Medium 28867761
2021 CLDN6 interacts with TAZ (transcriptional co-activator with PDZ-binding motif) and reduces TAZ levels, thereby suppressing c-MYC transcription, reducing glucose uptake and lactate production, and inhibiting aerobic glycolysis-dependent proliferation in breast cancer cells. Co-immunoprecipitation, metabolomic analysis (lactate levels), western blot, in vitro and in vivo proliferation assays International journal of molecular sciences Medium 35008557
2022 CLDN6 suppresses ERK signaling to inhibit breast cancer cell proliferation via the ERK/Sp1/cyclin D1 axis, and inhibits migration and invasion via ERK/IL-8 and downstream CXCR2/FAK signaling; ERK activator PMA reversed all these CLDN6-mediated effects. Overexpression, pharmacological rescue (PMA), western blot, wound healing, transwell invasion assay Cellular signalling Medium 35752352
2023 Through its PDZ-binding motif, CLDN6 interacts with JNK and upregulates JNK/c-Jun pathway; c-Jun transcriptionally upregulates WIP expression; WIP-dependent actin cytoskeleton assembly promotes autophagy, which in turn inhibits breast cancer metastasis; a positive feedback loop between CLDN6 and JNK/c-Jun was identified. Co-immunoprecipitation, immunofluorescence, ChIP, dual luciferase reporter assay, mRNA sequencing, phalloidin staining, western blot, in vivo lung metastasis models Journal of experimental & clinical cancer research High 36935496
2024 CLDN6 interacts with MAGI2 via its PDZ-binding motif to prevent KLF5 nuclear entry, thereby restraining SREBF1 transcription; reduced SREBP1 decreases de novo palmitic acid synthesis, impairing RAS palmitoylation and ESCRT-mediated plasma membrane localization of RAS, thus inhibiting oncogenic RAS activation and breast cancer progression. Co-immunoprecipitation, nuclear fractionation, immunofluorescence, IP-ABE (acyl-biotin exchange), ChIP, dual luciferase reporter assay, in vivo xenograft models, human palmitic acid and triglyceride assays Cellular & molecular biology letters High 39169280
2023 CLDN6 binds to ZO-1 through its PDZ-binding motif; this complex interacts with PTEN to regulate the AKT/MDM2 pathway, stabilize p53 by reducing ubiquitination, and promote p53 nuclear import, thereby inhibiting colorectal cancer cell proliferation. Co-immunoprecipitation, western blot, ubiquitination assay, nuclear fractionation, in vitro and in vivo proliferation assays Cellular signalling Medium 37852424
2025 CLDN6 recruits PBK to the cell membrane via the endosomal pathway and binds the DLG1/PBK complex, promoting PBK degradation via the ubiquitin-proteasome system (UPS); reduced PBK activity decreases the AKT/GSK3β/FYN axis, enhancing nuclear export of NRF2 and triggering NRF2-mediated ferroptosis in breast cancer cells. Co-immunoprecipitation, western blot, immunofluorescence, in vitro and in vivo functional assays, UPS inhibition rescue Cell death & disease Medium 39984471
2023 BLK and SRC (but not FGR or HCK) directly bind to the C-terminal cytoplasmic domain of CLDN6 in a phosphotyrosine-independent manner (shown by pull-down with recombinant proteins); BLK and SRC are essential for CLDN6-triggered epithelial differentiation and expression of retinoic acid receptor target genes in F9 cells. Immunoprecipitation, pull-down assay with recombinant proteins, genetic knockout (F9:Cldn6:Blk-/- and F9:Cldn6:Src-/-), phenotypic comparison Cells High 37443730
2024 CLDN6 interacts with RIP1 (receptor interacting protein 1) and activates the RIP1/ASK1/JNK axis to suppress aerobic glycolysis and inhibit NSCLC cell proliferation, invasion, and migration; CLDN6 promoter is silenced by DNA methylation in NSCLC. Co-immunoprecipitation, methylation-specific PCR, gain-of-function overexpression, Seahorse metabolic assay, in vivo tumor growth assay Journal of biochemical and molecular toxicology Medium 38462752
2025 CLDN6 interacts with LKB1 through its PDZ-binding motif, activating AMPK/ULK1 signaling and inducing protective autophagy; this protective autophagy promotes chemoresistance in breast cancer in response to adriamycin and paclitaxel. Chemotherapy increases CLDN6 expression via the ROS/GATA4 axis. Co-immunoprecipitation, western blot, autophagy assays, drug resistance assays, pharmacological inhibition rescue International journal of biological sciences Medium 40959289
2018 Knockdown of CLDN6 in endometrial carcinoma HEC-1B cells inhibits proliferation, migration, and invasion, and reduces phosphorylation of AKT, PI3K, and mTOR, placing CLDN6 upstream of the PI3K/AKT/mTOR signaling pathway in this cancer context. siRNA knockdown, CCK-8 proliferation assay, invasion/migration assays, western blot for pathway phosphorylation OncoTargets and therapy Low 30319275
2020 Knockdown of CLDN6 in HepG2 hepatocellular carcinoma cells inhibits proliferation, migration, and invasion and reduces activation of the EGFR/AKT/mTOR signaling pathway; EGFR inhibitor AG1478 suppresses the pro-proliferative effects of CLDN6 overexpression. siRNA knockdown, overexpression, western blot for pathway activation, pharmacological inhibition (AG1478), in vitro functional assays Cell biochemistry and function Low 32056244
2023 CLDN6 knockdown in hepatocellular carcinoma cells decreases phosphorylation of JAK2 and STAT3, reduces anti-apoptotic Bcl-2, and increases cleaved caspase-3 and Bax, placing CLDN6 upstream of the JAK2/STAT3 anti-apoptotic pathway in HCC. siRNA knockdown, overexpression, western blot for pathway phosphorylation, apoptosis assays (flow cytometry), transwell assay Translational cancer research Low 37588735
2009 CLDN6 gene expression in esophageal squamous cell carcinoma cell lines is silenced by DNA methylation of its promoter; treatment with the demethylating agent 5-aza-2'-deoxycytidine reduces methylation and restores CLDN6 mRNA expression. Methylation analysis, 5-aza-2'-deoxycytidine demethylation treatment, quantitative RT-PCR Oncology reports Medium 19288010
2026 CLDN6 sequesters PDLIM2 at the cell membrane, reducing nuclear PDLIM2-mediated RelA (NF-κB) ubiquitination; accumulated RelA transcriptionally upregulates METTL14, which enhances m6A modification and degradation of SOX4 mRNA, attenuating PI3K/Akt signaling and triggering autophagic cell death in breast cancer. Co-immunoprecipitation, nuclear fractionation, western blot, m6A modification assay, ChIP, luciferase reporter, in vitro and in vivo functional assays Cellular signalling Medium 42070760
2025 CLDN6 was identified as a defining surface marker of columnar trophoblast (bridging villous and extravillous compartments) during human chorion development; prospective isolation of CLDN6+ cells revealed their capacity to reacquire a proliferative villous state and, under directed cues, generate both syncytial and extravillous fates. Single-cell transcriptomics, spatial transcriptomics, prospective cell isolation using CLDN6 as surface marker, directed differentiation assays bioRxivpreprint Low

Source papers

Stage 0 corpus · 46 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2023 CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nature medicine 221 37872225
2019 Estrogen receptor β inhibits breast cancer cells migration and invasion through CLDN6-mediated autophagy. Journal of experimental & clinical cancer research : CR 117 31412908
2019 CLDN6 promotes tumor progression through the YAP1-snail1 axis in gastric cancer. Cell death & disease 75 31827075
2021 Targeting tumor lineage plasticity in hepatocellular carcinoma using an anti-CLDN6 antibody-drug conjugate. Science translational medicine 64 33536280
2017 CLDN6 promotes chemoresistance through GSTP1 in human breast cancer. Journal of experimental & clinical cancer research : CR 60 29116019
2005 Delayed epidermal permeability barrier formation and hair follicle aberrations in Inv-Cldn6 mice. Mechanisms of development 54 15908185
2009 Methylation of CLDN6, FBN2, RBP1, RBP4, TFPI2, and TMEFF2 in esophageal squamous cell carcinoma. Oncology reports 49 19288010
2016 CLDN6-induced apoptosis via regulating ASK1-p38/JNK signaling in breast cancer MCF-7 cells. International journal of oncology 43 27035750
2023 Preclinical Efficacy of the Antibody-Drug Conjugate CLDN6-23-ADC for the Treatment of CLDN6-Positive Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 40 36884217
2006 Role of the Cldn6 cytoplasmic tail domain in membrane targeting and epidermal differentiation in vivo. Molecular and cellular biology 40 16847338
2020 A SUMOylation-dependent HIF-1α/CLDN6 negative feedback mitigates hypoxia-induced breast cancer metastasis. Journal of experimental & clinical cancer research : CR 39 32093760
2021 CLDN6: From Traditional Barrier Function to Emerging Roles in Cancers. International journal of molecular sciences 38 34948213
2018 Knockdown of CLDN6 inhibits cell proliferation and migration via PI3K/AKT/mTOR signaling pathway in endometrial carcinoma cell line HEC-1-B. OncoTargets and therapy 33 30319275
2017 CLDN6 enhances chemoresistance to ADM via AF-6/ERKs pathway in TNBC cell line MDAMB231. Molecular and cellular biochemistry 31 29159771
2022 KHDRBS3 promotes paclitaxel resistance and induces glycolysis through modulated MIR17HG/CLDN6 signaling in epithelial ovarian cancer. Life sciences 30 35051418
2023 CLDN6 inhibits breast cancer metastasis through WIP-dependent actin cytoskeleton-mediated autophagy. Journal of experimental & clinical cancer research : CR 28 36935496
2017 SMAD2 Inactivation Inhibits CLDN6 Methylation to Suppress Migration and Invasion of Breast Cancer Cells. International journal of molecular sciences 27 28867761
2021 Association of CLDN6 and CLDN10 With Immune Microenvironment in Ovarian Cancer: A Study of the Claudin Family. Frontiers in genetics 24 34249076
2024 CLDN6 inhibits breast cancer growth and metastasis through SREBP1-mediated RAS palmitoylation. Cellular & molecular biology letters 23 39169280
2020 Downregulation of CLDN6 inhibits cell proliferation, migration, and invasion via regulating EGFR/AKT/mTOR signalling pathway in hepatocellular carcinoma. Cell biochemistry and function 22 32056244
2021 CLDN6 Suppresses c-MYC-Mediated Aerobic Glycolysis to Inhibit Proliferation by TAZ in Breast Cancer. International journal of molecular sciences 20 35008557
2021 The Expression of CLDN6 in Hepatocellular Carcinoma Tissue and the Effects of CLDN6 on Biological Phenotypes of Hepatocellular Carcinoma Cells. Journal of Cancer 19 34405008
2024 SAIL66, a next generation CLDN6-targeting T-cell engager, demonstrates potent antitumor efficacy through dual binding to CD3/CD137. Journal for immunotherapy of cancer 15 39401967
2023 Targeting CLDN6 in germ cell tumors by an antibody-drug-conjugate and studying therapy resistance of yolk-sac tumors to identify and screen specific therapeutic options. Molecular medicine (Cambridge, Mass.) 15 36991316
2022 CLDN6 inhibits breast cancer cell malignant behavior by suppressing ERK signaling. Cellular signalling 15 35752352
2020 Tight Junction-Related CLDN5 and CLDN6 Genes, and Gap Junction-Related GJB6 and GJB7 Genes Are Somatically Mutated in Gastric and Colorectal Cancers. Pathology oncology research : POR 14 32170581
2021 Effects of the Tight Junction Protein CLDN6 on Cell Migration and Invasion in High-Grade Meningioma. World neurosurgery 9 33862296
2022 The expression and the tumor suppressor role of CLDN6 in colon cancer. Molecular and cellular biochemistry 8 35701678
2023 The Src-Family Kinases SRC and BLK Contribute to the CLDN6-Adhesion Signaling. Cells 7 37443730
2020 CLDN6-mediates SB431542 action through MMPs to regulate the invasion, migration, and EMT of breast cancer cells. International journal of clinical and experimental pathology 7 32782677
2023 Downregulation of CLDN6 inhibits cell migration and invasion and promotes apoptosis by regulation of the JAK2/STAT3 signaling pathway in hepatocellular carcinoma. Translational cancer research 5 37588735
2023 CLDN6 inhibits colorectal cancer proliferation dependent on restraining p53 ubiquitination via ZO-1/PTEN axis. Cellular signalling 5 37852424
2025 CLDN6 triggers NRF2-mediated ferroptosis through recruiting DLG1/PBK complex in breast cancer. Cell death & disease 4 39984471
2024 CLDN6 inhibited cellular biological function of nonsmall cell lung cancer cells through suppressing aerobic glycolysis via the RIP1/ASK1/JNK axis. Journal of biochemical and molecular toxicology 4 38462752
2023 CLDN6 Suppresses Migration and Invasion of MCF-7 and SKBR-3 Breast Cancer Cells by Blocking the SMAD/Snail/MMP-2/9 Axis. Bulletin of experimental biology and medicine 4 37566248
2025 CLDN6 induces chemoresistance through protective autophagy in breast cancer. International journal of biological sciences 3 40959289
2025 Inhibition of DLK1 regulates AT2 differentiation and alleviates established pulmonary fibrosis by upregulating TTF-1/CLDN6. Respiratory research 2 40380180
2026 CLDN6 Expression Plasticity in Ovarian Cancer: Insights into Therapeutic Optimization for CLDN6-Targeted Immunotherapy. Cancer research communications 1 41628300
2026 Anti-cancer effects of carvacrol on NUF2, CASP3 and CLDN6 expression in T47D breast cancer cells. Naunyn-Schmiedeberg's archives of pharmacology 0 41569314
2026 Overcoming claudin family homology: discovery of ARC101, a highly potent CLDN6-specific T-cell engager with a novel CD3 binder for ovarian adenocarcinoma. mAbs 0 41804857
2026 Evaluating Claudin-6 and isochromosome 12p in the progression from germ cell neoplasia in situ to primary testicular germ cell tumor and post-chemotherapy teratoma: implications for CLDN6-targeted therapies. Therapeutic advances in medical oncology 0 41835342
2026 A novel CLDN6 nanobody-based bispecific T-cell engager delivered by self-amplifying RNA platform exhibits potent antitumor efficacy. Journal of nanobiotechnology 0 41882748
2026 The Functional Role and Molecular Characterization of the Therapeutic Target CLDN6 in Germ Cell Tumors. Andrology 0 41923292
2026 CLDN6 inhibits breast cancer growth by inducing autophagic cell death through SOX4 m6A modification. Cellular signalling 0 42070760
2026 Expression of the antibody-drug conjugate targets TROP2, CLDN6, B7-H3, and DLL3 in mesonephric-like adenocarcinoma of the female genital tract. Gynecologic oncology 0 42102523
2026 CLDN6 in Cancer: Biology, Clinical Significance, and Emerging Therapeutic Strategies. Pharmacological research 0 42259433

Missed literature

Know a paper Affinage missed for CLDN6? Flag it for the maintainers and the community.

No submissions yet.